Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
about
Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog TherapyManagement of HBV and HBV/HDV-Associated Liver CirrhosisCurrent and future directions for treating hepatitis B virus infectionManagement of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelinesIntrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis BAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Current hepatitis B treatment guidelines and future research directions.Alpha-interferon treatment in hepatitis BAdd-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.Meta-analysis: antiviral treatment for hepatitis D.Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes.Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.Inhibition of alpha interferon (IFN-α)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-α.Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfaComparison of three luminescent immunoassays for hepatitis B virus surface antigen quantification during the natural history of chronic hepatitis B virus infection.Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy?Evaluation of changes of serum hepatitis B surface antigen from a different perspective.Targeting the tumor microenvironment to enhance antitumor immune responsesPegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.Hepatitis B virus genotypes and variants.Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis.Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B.Serum hepatitis B surface antigen levels and their utility as a predictor of sustained virological response after antiviral treatment.Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response.Analysis of mutations in the S gene of hepatitis B virus strains in patients with chronic infection by online bioinformatics tools.Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.Immunomodulatory cytokines as therapeutic agents for melanomaPredictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysisTowards the elimination and eradication of hepatitis B.A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B.An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES StudyHBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patientsTransforming Growth Factor- β 1 Gene Polymorphism (T29C) in Egyptian Patients with Hepatitis B Virus Infection: A Preliminary StudyEffect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.HBsAg Quantification in Clinical Practice.SASLT practice guidelines for the management of hepatitis B virus.HBsAg levels in HBeAg-positive chronic hepatitis B patients with different immune conditions.Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
P2860
Q26740161-E37626F8-FE2D-4396-9C4F-6195E75F94E4Q26740323-D6120502-D9EB-4DED-8932-10309410778BQ26851240-D4EE1D0A-8B46-4D41-B9B3-27FBD92428C7Q27000080-11439D96-5313-4985-9944-33B183FC83B0Q27318089-93B25D00-9300-4DE6-AAA0-ABB7F9A35402Q30391932-02C33F0C-74F6-47DB-B644-712D87811B61Q30487002-BB1D9C76-304D-4C77-B0A2-F65BB692D03BQ33592755-BB8CC215-54A7-4B88-84AD-790354E3C5DFQ33604145-B351A305-8F0A-490F-BC6C-4F0E0436854CQ34137291-B7DD8ABE-D3DA-4AAB-90D9-DADB21D67878Q34138307-5984FDCC-FE07-4C85-A7C1-77FD4CD7DB82Q34189348-FDEA5E7A-3229-448F-B63F-E4D2761C9D83Q34252292-EB61863C-ECB9-4812-8F14-5CC12779CB53Q34305346-162877D0-F910-45C8-97E1-F572722B6530Q34556199-ACF9BC5E-3D60-4FAF-9994-144C44D7536BQ34592952-8084814E-98B1-4BCB-A85A-196470F65688Q35118955-3D85F360-DB45-47DB-8D67-5FBBAFC9F464Q35152364-99315981-D9BE-4044-9C92-4FB3F9CEFB6DQ35176307-050CA7B6-BC97-48CE-A5A6-E6A2C111E68DQ35250340-0272EC31-7EE6-415B-A56A-B8BA6D58F169Q35663838-0B2C92E4-45BA-4E4C-BA59-584FAB42D587Q35688409-C6799DE7-E286-474E-84B0-84CB8190F507Q35739079-54793F94-3BA7-439F-AB31-1D3BFFFD3F4BQ35866293-963E5C26-FB83-4E40-8E19-6A5139DAE31AQ36220194-4931293C-C392-436A-A7B1-943BE44C584BQ36457659-34C637A4-71C3-4FAA-BBA0-13F22AA06ECBQ36506360-63F44044-48A1-4814-A9DB-8A9DA33BB264Q36614504-57DDB91B-E670-4F0B-8A82-D7E23ABF9727Q37070203-A9EA1A53-6E3E-4805-AA19-A3E45E77CE30Q37087279-ECE1A42D-5810-425E-AA8C-D256A201A916Q37098214-FF22C4D0-3DB8-4459-B45E-2958275102C1Q37129038-4F3A68A8-D768-4577-B4FA-AA35C5BCC172Q37206545-F1068B27-946B-4235-8E22-363C75BB1F01Q37374481-E3822224-66A4-44BA-9C82-306724B9D38FQ37426804-229D456B-02FB-46C4-BD60-C23C8E222F22Q37501060-3BC23868-5B6F-4790-9116-15CD9A28BDD6Q37614037-FF1A35AB-D5D5-4D97-AECA-E9CE4D604CFDQ37634822-AADC3C39-B695-4857-9705-FED679F210C2Q37708054-3860E113-9037-4E05-A8EF-AA861F974170Q37825532-D91E21FE-0C22-4B9F-8DE8-6883AE76205E
P2860
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Prediction of sustained respon ...... tis B surface antigen decline.
@en
Prediction of sustained respon ...... tis B surface antigen decline.
@nl
type
label
Prediction of sustained respon ...... tis B surface antigen decline.
@en
Prediction of sustained respon ...... tis B surface antigen decline.
@nl
prefLabel
Prediction of sustained respon ...... tis B surface antigen decline.
@en
Prediction of sustained respon ...... tis B surface antigen decline.
@nl
P2093
P356
P1433
P1476
Prediction of sustained respon ...... tis B surface antigen decline.
@en
P2093
Charles A B Boucher
Harry L A Janssen
Milan J Sonneveld
Vincent Rijckborst
P304
P356
10.1002/HEP.23844
P407
P577
2010-10-01T00:00:00Z